ALLMedicine™ Mastocytosis Center

Jul 31st, 2020 - Myeloid neoplasm with blasts showing mast cell (MC)-differentiation and MC-component less than 10% of all nucleated cells but not fulfilling the criteria for systemic mastocytosis with associated hematological neoplasm (SM-AHN) or myelomastocytic ...

Jul 29th, 2020 - Visual Dermatology: Diffuse Cutaneous Mastocytosis With Bullous Lesions.|2020|Tan Q,Zhang J,|

Jul 27th, 2020 - Elevated basal serum tryptase is associated with severe systemic anaphylaxis, most notably caused by Hymenoptera envenomation. While clonal mast cell disease is culprit in some individuals, it does not fully explain this clinical association. To d...

Jul 21st, 2020 - The current article highlights recent developments in the field of pediatric cutaneous mastocytosis. Mastocytosis is a spectrum of conditions that range from fleetingly benign to aggressively malignant. Through recognizing the natural progression ...

Jul 20th, 2020 - Atopic diseases worsen with psychological stress, but how stress contributes to their pathogenesis is still not clear. We review the evidence supporting the premise that stress contributes to allergic and inflammatory processes via stimulation of ...

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

May 19th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...

Jul 31st, 2020 - Myeloid neoplasm with blasts showing mast cell (MC)-differentiation and MC-component less than 10% of all nucleated cells but not fulfilling the criteria for systemic mastocytosis with associated hematological neoplasm (SM-AHN) or myelomastocytic ...

Jul 29th, 2020 - Visual Dermatology: Diffuse Cutaneous Mastocytosis With Bullous Lesions.|2020|Tan Q,Zhang J,|

Jul 27th, 2020 - Elevated basal serum tryptase is associated with severe systemic anaphylaxis, most notably caused by Hymenoptera envenomation. While clonal mast cell disease is culprit in some individuals, it does not fully explain this clinical association. To d...

Jul 21st, 2020 - The current article highlights recent developments in the field of pediatric cutaneous mastocytosis. Mastocytosis is a spectrum of conditions that range from fleetingly benign to aggressively malignant. Through recognizing the natural progression ...

Jul 20th, 2020 - Atopic diseases worsen with psychological stress, but how stress contributes to their pathogenesis is still not clear. We review the evidence supporting the premise that stress contributes to allergic and inflammatory processes via stimulation of ...

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Jul 9th, 2019 - However, the Expert Committee still did not define either the length of time of flushing or nontransient erythema. It also did not specify convex surfaces of the face with periocular sparing as the characteristic pattern or provide additional info.

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.